Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PRTA

Prothena Corporation plc

Apr 13 • 04:00PM ET

10.31

-0.19 -1.81 %

Healthcare • Biotechnology • Ireland • NASD

Peers: VRTX BIIB ALNY IONS SRPT NBIX EXEL ACAD ARWR CLDX

| Held by: XBI IWM VXF IWN IBB SCHA VTWO DFMC DFAS VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.53	Insider Own	19.39%	Shs Outstand	53.83M	Perf Week	2.69%
Market Cap	555.02M	Forward P/E	-	EPS next Y	-0.83	Insider Trans	0.00%	Shs Float	43.39M	Perf Month	10.74%
Enterprise Value	255.86M	PEG	-	EPS next Q	-0.35	Inst Own	88.20%	Short Float	16.17%	Perf Quarter	12.19%
Income	-244.09M	P/S	57.34	EPS this Y	105.45%	Inst Trans	5.79%	Short Ratio	13.58	Perf Half Y	0.10%
Sales	9.68M	P/B	1.98	EPS next Y	-435.13%	ROA	-55.86%	Short Interest	7.02M	Perf YTD	7.96%
Book/sh	5.21	P/C	1.80	EPS next 5Y	-	ROE	-63.62%	52W High	11.69 -11.80%	Perf Year	0.88%
Cash/sh	5.71	P/FCF	-	EPS past 3/5Y	-22.46% -10.24%	ROIC	-85.36%	52W Low	4.32 138.66%	Perf 3Y	-80.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-43.57% 62.56%	Gross Margin	62.03%	Volatility	3.70% 4.22%	Perf 5Y	-55.88%
Dividend TTM	-	EV/Sales	26.43	EPS Y/Y TTM	-99.35%	Oper. Margin	-1905.82%	ATR (14)	0.44	Perf 10Y	-77.91%
Dividend Ex-Date	-	Quick Ratio	7.72	Sales Y/Y TTM	-92.83%	Profit Margin	-2520.57%	RSI (14)	61.55	Recom	2.17
Dividend Gr. 3/5Y	- -	Current Ratio	7.72	EPS Q/Q	62.77%	SMA20	7.96%	Beta	-0.33	Target Price	21.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-99.01%	SMA50	11.13%	Rel Volume	0.65	Prev Close	10.50
Employees	67	LT Debt/Eq	0.02	Earnings	Feb 19 AMC	SMA200	14.36%	Avg Volume	516.47K	Price	10.31
IPO	Dec 21, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	28.39% -98.43%	Trades		Volume	334,062	Change	-1.81%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	BofA Securities	Neutral → Underperform	$4
May-27-25	Downgrade	Oppenheimer	Outperform → Perform
May-27-25	Downgrade	Jefferies	Buy → Hold	$6
May-27-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$40
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $38
Dec-12-23	Initiated	Deutsche Bank	Buy	$62
Apr-24-23	Initiated	SVB Securities	Outperform	$80
Jan-27-23	Initiated	Piper Sandler	Overweight	$94
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$52 → $55
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform	$77
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral	$12 → $49
Jun-08-21	Reiterated	Oppenheimer	Outperform	$45 → $54
May-26-21	Initiated	Citigroup	Buy	$39
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$14 → $28
Feb-12-21	Upgrade	Jefferies	Hold → Buy	$15 → $30
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy	$29
Dec-07-20	Initiated	H.C. Wainwright	Buy	$22
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform	$16

Show Previous Ratings

Apr-10-26 04:05PM	Prothena Announces Leadership Team Updates (Business Wire)
Mar-21-26 04:05PM	Prothena Partners Present Data Supporting Next Generation Treatments for Parkinsons and Alzheimers Disease at AD/PD 2026 (Business Wire)
Mar-09-26 04:05PM	Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Mar-03-26 09:55AM	Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade (Zacks)
Feb-27-26 04:15PM	Prothena Announces up to $100 Million Share Repurchase Plan (Business Wire) +8.42%
11:27AM	Loading…
Feb-20-26 11:27AM	Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus (Zacks)
08:30AM	Prothena Corporation plc Q4 2025 Earnings Call Summary (Moby)
12:02AM	Prothena Corp PLC (PRTA) Q4 2025 Earnings Call Highlights: Strategic Advancements and Financial ... (GuruFocus.com)
Feb-19-26 07:08PM	Prothena Q4 Earnings Call Highlights (MarketBeat)
05:35PM	Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:34PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-16-26 09:54AM	Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead? (Zacks)
Feb-13-26 11:40AM	FTRE vs. PRTA: Which Stock Is the Better Value Option? (Zacks)
Feb-12-26 04:05PM	Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 (Business Wire)
12:00PM	Loading…
Jan-21-26 12:00PM	All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy (Zacks)
Jan-07-26 08:06AM	Fortrea Holdings Inc. (FTRE) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Dec-12-25 04:05PM	Prothena Announces Board of Directors Update (Business Wire)
Nov-19-25 04:05PM	Prothena Announces Poster Presentation on its TDP-43 CYTOPE Program at Neuroscience 2025 (Business Wire)
Nov-11-25 09:00AM	Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA (Business Wire)
Nov-07-25 10:32AM	Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus (Zacks)
Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:46PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Oct-30-25 04:05PM	Prothena to Report Third Quarter 2025 Financial Results on November 6 (Business Wire)
Oct-22-25 03:33PM	Prothena Corporation plc (PRTA): A Bull Case Theory (Insider Monkey)
Oct-01-25 04:45PM	Prothenas Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimers Disease (Business Wire)
Sep-11-25 10:01AM	Prothena Down 40% Year to Date: What Lies Ahead for the Stock? (Zacks)
Sep-03-25 11:30AM	Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-25 04:05PM	Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference (Business Wire)
04:05PM	Loading…
Aug-27-25 04:05PM	Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program (Business Wire)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
Aug-06-25 09:00AM	Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy (Business Wire) +12.66%
Aug-04-25 05:50PM	Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Prothena: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
Jul-29-25 10:00AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline (Zacks)
Jul-28-25 04:05PM	Prothena to Report Second Quarter 2025 Financial Results on August 4 (Business Wire)
Jul-24-25 10:46AM	Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well (Zacks)
Jul-17-25 01:07PM	AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies (Zacks)
Jul-04-25 01:51PM	PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? (Zacks)
Jun-20-25 07:22AM	Prothena to lay off majority of staff; Zealand shares obesity drug data (BioPharma Dive)
Jun-18-25 04:05PM	Prothena Announces Corporate Restructuring (Business Wire)
Jun-17-25 01:30PM	Roche's Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) (Insider Monkey)
09:16AM	Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus (TipRanks)
Jun-16-25 10:22AM	Roche, waving off study failures, commits to Phase 3 trials for Parkinsons drug (BioPharma Dive) +11.42%
09:49AM	RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development (Zacks)
01:06AM	Prothenas Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease (Business Wire)
May-29-25 03:40PM	Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails (Insider Monkey)
May-28-25 01:55PM	Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform (Insider Monkey)
May-27-25 01:08PM	Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results (Insider Monkey) -30.40%
10:20AM	Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down (Zacks)
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
07:43AM	Why Is Prothena Stock Trading Lower On Tuesday? (Benzinga)
May-26-25 06:16AM	Prothenas Phase III trial for AL amyloidosis treatment misses endpoint (Clinical Trials Arena)
May-23-25 04:05PM	Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint (Business Wire) -30.40%
May-09-25 01:28PM	Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025 (Zacks)
08:29AM	Is Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 05:50PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Prothena: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-07-25 12:44PM	Prothena Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 04:05PM	Prothena to Report First Quarter 2025 Financial Results on May 8 (Business Wire) -5.22%
Apr-16-25 11:49AM	Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi (Zacks)
Feb-21-25 02:15AM	Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ... (GuruFocus.com)
Feb-20-25 05:25PM	Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:22PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-13-25 04:05PM	Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 (Business Wire)
Dec-30-24 04:05PM	Prothena Announces Board of Directors Update (Business Wire) -6.92%
Dec-19-24 04:22PM	Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease (Investor's Business Daily) +33.97%
08:09AM	Prothenas Parkinsons study fails primary endpoint despite some success (Clinical Trials Arena)
01:05AM	Roches Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinsons Disease (Business Wire)
Dec-12-24 11:30AM	Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? (Zacks)
Nov-12-24 05:55PM	Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:56PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
Nov-05-24 04:05PM	Prothena to Report Third Quarter 2024 Financial Results on November 12 (Business Wire) +8.71%
Oct-29-24 12:00PM	Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
04:48AM	Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Oct-18-24 03:01PM	State Street Corp's Strategic Reduction in Prothena Corp PLC Holdings (GuruFocus.com)
Sep-27-24 04:05PM	Prothena Announces Leadership Team Updates (Business Wire) -16.56%
Aug-29-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Aug-19-24 12:00PM	What Makes Prothena (PRTA) a New Buy Stock (Zacks)
Aug-18-24 12:28AM	Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks (Insider Monkey)
Aug-17-24 08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-09-24 09:16AM	Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues (Zacks)
Aug-08-24 06:40PM	Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:33PM	Prothena: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Aug-01-24 04:05PM	Prothena to Report Second Quarter 2024 Financial Results on August 8 (Business Wire) -5.20%
Jul-25-24 10:02AM	Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-24-24 08:48AM	Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last? (Zacks)
Jun-11-24 04:07PM	Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower (Investor's Business Daily)
12:20PM	Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win (Investor's Business Daily)
Jun-07-24 11:30AM	Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report? (Zacks)
May-29-24 10:26AM	Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate (Zacks)
08:46AM	BMS stakes $80m on Prothenas neurodegenerative candidate (Pharmaceutical Technology)
May-28-24 04:05PM	Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration (Business Wire)

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	10% Owner	May 02 '25	Sale	8.36	3,317,938	27,744,929	8,266,342	May 06 07:06 PM
EcoR1 Capital, LLC	10% Owner	May 06 '25	Sale	7.64	1,984,053	15,164,712	5,304,596	May 06 07:06 PM
EcoR1 Capital, LLC	10% Owner	May 05 '25	Sale	8.11	977,693	7,930,166	7,288,649	May 06 07:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRTA

Prothena Corporation plc

Upgrade your Finviz experience